FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 322 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives December 14, 2023 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of... January 15, 2020 What to Know About Getting Access to New Cancer Advances Presented... September 14, 2022 Load more HOT NEWS 5 questions the NHS Workforce Plan for England needs to answer Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab
